This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.62% per year. These returns cover a period from January 1, 1988 through June 2, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
earnings-estimates-revisions: Archive
Performant Healthcare (PHLT) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Performant Healthcare (PHLT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
PHLTPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Abbott (ABT) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Abbott (ABT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ABTPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
All You Need to Know About MasterCard (MA) Rating Upgrade to Buy
by Zacks Equity Research
MasterCard (MA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
MAPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Wall Street Analysts Believe Manchester United (MANU) Could Rally 29.31%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 29.3% in Manchester United (MANU). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
MANUPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Summit Therapeutics (SMMT) Could Rally 63.02%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Summit Therapeutics (SMMT) points to a 63% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
SMMTPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict a 25.99% Upside in Verona Pharma (VRNA): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 26% in Verona Pharma (VRNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
VRNANegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See Abercrombie (ANF) as a Buy: Should You Invest?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Abercrombie (ANF) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
ANFPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Adobe (ADBE) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Adobe (ADBE) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
ADBEPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Wall Street Bulls Look Optimistic About Lilly (LLY): Should You Buy?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Lilly (LLY) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
LLYPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Wall Street Analysts See OneSpan (OSPN) as a Buy: Should You Invest?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in OneSpan (OSPN). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
OSPNNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Should You Invest in ARKO (ARKO) Based on Bullish Wall Street Views?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in ARKO (ARKO). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
ARKOPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is MasterCard (MA) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in MasterCard (MA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
MAPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Brokers Suggest Investing in Roblox (RBLX): Read This Before Placing a Bet
by Zacks Equity Research
The average brokerage recommendation (ABR) for Roblox (RBLX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
RBLXPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Brokers Suggest Investing in AT&T (T): Read This Before Placing a Bet
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), AT&T (T) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
TPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Brokers Suggest Investing in CVS Health (CVS): Read This Before Placing a Bet
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in CVS Health (CVS). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
CVSNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
VKTXPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Constellation Brands (STZ) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Constellation Brands (STZ) give a sense of how the business performed in the quarter ended May 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
STZNegative Net Change
earnings earnings-estimates-revisions earnings-surprise
Compared to Estimates, MSC Industrial (MSM) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for MSC Industrial (MSM) give a sense of how the business performed in the quarter ended May 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
MSMNegative Net Change
earnings earnings-estimates-revisions earnings-surprise
Earnings Estimates Rising for Micron (MU): Will It Gain?
by Zacks Equity Research
Micron (MU) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
MUNegative Net Change
earnings earnings-estimates earnings-estimates-revisions price-performance stock-performance zacks-consensus-estimate zacks-rank
Will Werner (WERN) Gain on Rising Earnings Estimates?
by Zacks Equity Research
Werner (WERN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
WERNNegative Net Change
earnings earnings-estimates earnings-estimates-revisions price-performance stock-performance zacks-consensus-estimate zacks-rank
Earnings Estimates Rising for Cracker Barrel (CBRL): Will It Gain?
by Zacks Equity Research
Cracker Barrel (CBRL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
CBRLNegative Net Change
earnings earnings-estimates earnings-estimates-revisions price-performance stock-performance zacks-consensus-estimate zacks-rank
Freshworks (FRSH) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Freshworks (FRSH) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
FRSHPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Kone Oyj (KNYJY) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Kone Oyj (KNYJY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
KNYJYNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Advanced Energy (AEIS) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Advanced Energy (AEIS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AEISPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
What Makes Sage Therapeutics (SAGE) a New Buy Stock
by Zacks Equity Research
Sage Therapeutics (SAGE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SAGENegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank